TabletsClinical Overview
Memantine Hydrochloride is an uncompetitive, low-to-moderate affinity, voltage-dependent N-methyl-D-aspartate (NMDA) receptor antagonist. Pathological chronic exposure to high glutamate concentrations produces excitotoxic neuronal death in Alzheimer's disease; memantine blocks pathological tonic glutamate influx through NMDA channels while preserving physiological phasic neurotransmission necessary for learning and memory. Indicated for moderate-to-severe dementia of the Alzheimer's type.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily with water, with or without food. Titrate dose gradually in weekly increments to the target maintenance dose (20 mg/day). Follow doctor's schedule.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dizziness, headache, confusion, constipation, somnolence, hypertension, coughing. Rare/Severe: Seizures, heart failure, psychosis, pancreatitis, and acute renal failure.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Caution in patients with severe renal impairment (dosage reduction required if CrCl < 30 mL/min) and history of seizure disorders. Alkalinizing agents (sodium bicarbonate, carbonic anhydrase inhibitors) reduce renal clearance of memantine, increasing toxicity risk.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Donepezil 5mg + Memantine 5mg Tablets
Donepezil and Memantine is a complementary dual-mechanism formulation for moderate-to-severe dementia. Donepezil, a reversible piperidine acetylcholinesterase inhibitor, increases acetylcholine concentrations at cerebral synapses, while memantine, an uncompetitive NMDA receptor antagonist, protects cholinergic neurons against pathological chronic glutamate-mediated excitotoxicity. Indicated for moderate-to-severe dementia of the Alzheimer's type.
Donepezil 5mg + Memantine 10mg Tablets
Donepezil and Memantine is a complementary dual-mechanism formulation for moderate-to-severe dementia. Donepezil, a reversible piperidine acetylcholinesterase inhibitor, increases acetylcholine concentrations at cerebral synapses, while memantine, an uncompetitive NMDA receptor antagonist, protects cholinergic neurons against pathological chronic glutamate-mediated excitotoxicity. Indicated for moderate-to-severe dementia of the Alzheimer's type.